Preferences, satisfaction and decision-making processes in osteoporosis treatment: a systematic review of the literature
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: To synthesize information available in the literature on patients' preferences and satisfaction with osteoporosis treatment and their unmet needs on the treatment decision-making process. Materials & methods: Systematic literature review consulting international database and grey literature of articles published between January 1, 2009 and January 1, 2019. Results: Nineteen publications were reviewed, 79% of them focused on evaluating the importance that patients attached to the mode and frequency of administration, adverse events and treatment efficacy. 21% of them provided information about treatment satisfaction and 26% regarding unmet needs on treatment-decision making process. Conclusion: Aligning treatment with patients' preferences, promoting physician-patient communication and identifying patients' concerns with treatment may contribute to improve treatment satisfaction and adherence and ultimately achieve the treatment goal.
Supplementary Material
File (suppl_file.docx)
- Download
- 16.25 KB
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am. J. Med. 94(6), 646–650 (1993).
2.
Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ. Tech. Rep. Ser. 843, 1–129 (1994).
3.
Hernlund E, Svedbom A, Ivergard M et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch. Osteoporos. 8, 136 (2013).
4.
Rizzoli R. Postmenopausal osteoporosis: assessment and management. Best Pract. Res. Clin. Endocrinol. Metab. 32(5), 739–757 (2018).
5.
Kim SC, Kim M-S, Sanfélix-Gimeno G et al. Use of osteoporosis medications after hospitalisation for hip fracture: a cross-national study. Am. J. Med. 128(5), 519–526.e511 (2015).
6.
Lems WF, Dreinhofer KE, Bischoff-Ferrari H et al. EULAR/EFORT recommendations for management of patients older than 50 years with a fragility fracture and prevention of subsequent fractures. Ann. Rheum. Dis. 76(5), 802–810 (2017).
7.
Vidal M, Thibodaux RJ, Neira LFV, Messina OD. Osteoporosis: a clinical and pharmacological update. Clin. Rheumatol. 38(2), 385–395 (2019).
8.
Sacristan JA. Patient-centered medicine and patient-oriented research: improving health outcomes for individual patients. BMC Med. Inform. Decis. Mak. 13, 6 (2013).
• Provides background for patient-centered medicine.
9.
Barry MJ, Edgman-Levitan S. Shared decision making–pinnacle of patient-centered care. N. Engl. J. Med. 366(9), 780–781 (2012).
10.
Reginster JY, Rabenda V, Neuprez A. Adherence, patient preference and dosing frequency: understanding the relationship. Bone 38, S2–S6 (2006).
11.
Lewiecki EM. Risk communication and shared decision making in the care of patients with osteoporosis. J. Clin. Densitom. 13(4), 335–345 (2010).
12.
Alami S, Hervouet L, Poiraudeau S, Briot K, Roux C. Barriers to effective postmenopausal osteoporosis treatment: a qualitative study of patients' and practitioners' views. PLoS OME 11(6), e0158365 (2016).
13.
Hiligsmann M, Bours SPG, Boonen A. A review of patient preferences for osteoporosis drug treatment. Curr. Rheumatol. Rep. 17(6), 61 (2015).
14.
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339, b2535 (2009).
15.
OCEBM Levels of Evidence Working Group. The Oxford 2011 Levels of Evidence. Oxford Centre for Evidence-Based Medicine. Available at: www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence
16.
Fobelo Lozano MJ, Sanchez-Fidalgo S. Adherence and preference of intravenous zoledronic acid for osteoporosis versus other bisphosphonates. Eur. J. Hosp. Pharm. Sci. Pract. 26(1), 4–9 (2019).
•• Reviews preferences and satisfaction with once-yearly intravenous zoledronic acid treatment versus another bisphosphonate.
17.
Hiligsmann M, Dellaert BG, Dirksen CD et al. Patients' preferences for osteoporosis drug treatment: a discrete-choice experiment. Arthritis Res. Ther. 16(1), R36 (2014).
18.
Hiligsmann M, Dellaert BG, Dirksen CD et al. Patients' preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment. Rheumatology (Oxford) 56(7), 1167–1176 (2017).
•• This discrete choice experiment estimates and compare the preferences of patients with osteoporosis by the attributes of the treatments in eight European countries.
19.
Kendler DL, Bessette L, Hill CD et al. Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. Osteoporos. Int. 21(5), 837–846 (2010).
•• Study that assesses the preference and satisfaction of patients with osteoporosis treated with denosumab and alendronate.
20.
Kastelan D, Lozo P, Stamenkovic D et al. Preference for weekly and monthly bisphosphonates among patients with postmenopausal osteoporosis: results from the Croatian PROMO Study. Clin. Rheumatol. 28(3), 321–326 (2009).
•• Compares weekly vs. monthly administration regimens.
21.
Payer J, Cierny D, Killinger Z, Sulkova I, Behuliak M, Celec P. Preferences of patients with post-menopausal osteoporosis treated with bisphosphonates–the VIVA II study. J. Int. Med. Res. 37(4), 1225–1229 (2009).
22.
Bonnick SL, Silverman S, Tanner SB et al. Patient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate. J. Womens Health (Larchmt.) 18(7), 935–943 (2009).
23.
Kendler DL, Macarios D, Lillestol MJ et al. Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the Denosumab Adherence Preference Satisfaction study. Menopause 21(1), 25–32 (2014).
24.
Oral A, Lorenc R. Compliance, persistence, and preference outcomes of postmenopausal osteoporotic women receiving a flexible or fixed regimen of daily risedronate: a multicenter, prospective, parallel group study. Acta Orthop. Traumatol. Turc. 49(1), 67–74 (2015).
25.
Neuner JM, Schapira MM. Patient perceptions of osteoporosis treatment thresholds. J. Rheumatol. 41(3), 516–522 (2014).
26.
Silverman S, Calderon A, Kaw K et al. Patient weighting of osteoporosis medication attributes across racial and ethnic groups: a study of osteoporosis medication preferences using conjoint analysis. Osteoporos. Int. 24(7), 2067–2077 (2013).
27.
Hiligsmann M, Van Durme C, Geusens P et al. Nominal group technique to select attributes for discrete choice experiments: an example for drug treatment choice in osteoporosis. Patient Prefer. Adherence 7, 133–139 (2013).
•• Shows the most important attributes for patients in osteoporosis treatment in order from 1 to 12.
28.
De Bekker-Grob EW, Essink-Bot ML, Meerding WJ, Koes BW, Steyerberg EW. Preferences of GPs and patients for preventive osteoporosis drug treatment: a discrete-choice experiment. Pharmacoeconomics 27(3), 211–219 (2009).
29.
Darba J, Restovic G, Kaskens L et al. Patient preferences for osteoporosis in Spain: a discrete choice experiment. Osteoporos. Int. 22(6), 1947–1954 (2011).
30.
Vlak T, Kastelan D, Lozo P et al. Monthly or weekly bisphosphonate? Evaluation of satisfaction in patients with postmenopausal osteoporosis using OPSAT-Q questionnaire during the BOOSTER study in Croatia. Clin. Rheumatol. 30(12), 1549–1554 (2011).
31.
Jensen AL, Wind G, Langdahl BL, Lomborg K. The impact of multifaceted osteoporosis group education on patients' decision-making regarding treatment options and lifestyle changes. J. Osteoporos. 2018, 9703602 (2018).
32.
Jakobsen PR, Hermann AP, Sondergaard J, Wiil UK, Dixon RF, Clemensen J. Left in limbo – experiences and needs among postmenopausal women newly diagnosed with osteoporosis without preceding osteoporotic fractures: a qualitative study. Post. Reprod. Health 24(1), 26–33 (2018).
33.
Sale JE, Gignac MA, Hawker G et al. Decision to take osteoporosis medication in patients who have had a fracture and are ‘high’ risk for future fracture: a qualitative study. BMC Musculoskelet. Disord. 12, 92 (2011).
34.
Mazor KM, Velten S, Andrade SE, Yood RA. Older women's views about prescription osteoporosis medication: a cross-sectional, qualitative study. Drugs Aging 27(12), 999–1008 (2010).
35.
Gold DT, Safi W, Trinh H. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr. Med. Res. Opin. 22(12), 2383–2391 (2006).
36.
Keen R, Jodar E, Iolascon G et al. European women's preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency. Curr. Med. Res. Opin. 22(12), 2375–2381 (2006).
37.
Silverman SL, Gold DT. Compliance and persistence with osteoporosis therapies. Curr. Rheumatol. Rep. 10(2), 118–122 (2008).
38.
Clowes JA, Peel NFA, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: A randomized controlled trial. J. Clin. Endocrinol. Metab. 89(3), 1117–1123 (2004).
39.
Bogelund M, Vilsboll T, Faber J, Henriksen JE, Gjesing RP, Lammert M. Patient preferences for diabetes management among people with type 2 diabetes in Denmark – a discrete choice experiment. Curr. Med. Res. Opin. 27(11), 2175–2183 (2011).
40.
Boye KS, Matza LS, Walter KN, Van Brunt K, Palsgrove AC, Tynan A. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur. J. Health Econ. 12(3), 219–230 (2011).
41.
Jendle J, Torffvit O, Ridderstrale M, Lammert M, Ericsson A, Bogelund M. Willingness to pay for health improvements associated with anti-diabetes treatments for people with type 2 diabetes. Curr. Med. Res. Opin. 26(4), 917–923 (2010).
42.
Fifer S, Rose J, Hamrosi KK, Swain D. Valuing injection frequency and other attributes of type 2 diabetes treatments in Australia: a discrete choice experiment. BMC Health Serv. Res. 18(1), 675 (2018).
43.
Rydén A, Chen S, Flood E, Romero B, Grandy S. Discrete choice experiment attribute selection using a multinational interview study: treatment features important to patients with Type 2 diabetes mellitus. Patient 10(4), 475–487 (2017).
44.
Goldshtein I, Rouach V, Shamir-Stein N, Yu J, Chodick G. Role of side effects, physician involvement, and patient perception in non-adherence with oral bisphosphonates. Adv. Ther. 33(8), 1374–1384 (2016).
45.
Hamilton B, Mccoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos. Int. 14(3), 259–262 (2003).
46.
Turbí C, Herrero-Beaumont G, Cebes J et al. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin. Therapeut. 26(2), 245–256 (2004).
47.
Modi A, Sen S, Adachi JD et al. Gastrointestinal symptoms and association with medication use patterns, adherence, treatment satisfaction, quality of life, and resource use in osteoporosis: baseline results of the MUSIC-OS study. Osteoporos. Int. 27(3), 1227–1238 (2016).
48.
Woo C, Gao G, Wade S, Hochberg MC. Gastrointestinal side effects in postmenopausal women using osteoporosis therapy: 1-year findings in the POSSIBLE US study. Curr. Med. Res. Opin. 26(4), 1003–1009 (2010).
49.
Freemantle N, Satram-Hoang S, Tang ET et al. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomised, crossover comparison with alendronate in postmenopausal women. Osteoporosis Int. 23(1), 317–326 (2012).
50.
Hall SF, Edmonds SW, Lou Y et al. Patient-reported reasons for nonadherence to recommended osteoporosis pharmacotherapy. J. Am. Pharm. Assoc. 57(4), 503–509 (2017).
51.
Montgomery AA, Harding J, Fahey T. Shared decision making in hypertension: the impact of patient preferences on treatment choice. Fam. Pract. 18(3), 309–313 (2001).
52.
Krahn M, Naglie G. The next step in guideline development: incorporating patient preferences. JAMA 300(4), 436–438 (2008).
53.
Iversen MD, Vora RR, Servi A, Solomon DH. Factors affecting adherence to osteoporosis medications: a focus group approach examining viewpoints of patients and providers. J. Geriatr. Phys. Ther. 34(2), 72–81 (2011).
54.
Kendler D, Lillestol MJ, Moffett AH et al. Influence of patient perceptions and preferences about osteoporosis medication on adherence in the denosumab adherence, preference, and satisfaction (DAPS) study. Menopause 19(12), 1390 (2012).
55.
Cranney A, O'connor AM, Jacobsen MJ et al. Development and pilot testing of a decision aid for postmenopausal women with osteoporosis. Patient Educ. Couns. 47(3), 245–255 (2002).
56.
Montori VM, Shah ND, Pencille LJ et al. Use of a decision aid to improve treatment decisions in osteoporosis: the osteoporosis choice randomised trial. Am. J. Med. 124(6), 549–556 (2011).
57.
Paskins Z, Torres Roldan VD, Hawarden AW et al. Quality and effectiveness of osteoporosis treatment decision aids: a systematic review and environmental scan. Osteoporos. Int. 31(10), 1837–1851 (2020).
Information & Authors
Information
Published In
Pages: 629 - 645
PubMed: 33880940
Copyright
© 2021 Future Medicine Ltd.
History
Received: 1 October 2020
Accepted: 12 March 2021
Published online: 21 April 2021
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Preferences, satisfaction and decision-making processes in osteoporosis treatment: a systematic review of the literature. (2021) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2020-0216
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Xavier Nogués Solán, Diana Ovejero, Carmen Gimenez-Argente, Jaime Rodríguez-Morera, Abora Rial-Villavecchia, Eloi García-Vives, María Lourdes Cos, Jade Soldado-Folgado, Mariona Llaberia, Ariadna Brasé Arnau, Irene Petit, Rosa Ana Sabaté, Jose María Mora-Luján, Charlotte Beaudart, Stuart Silverman, Mickael Hiligsmann, Natalia Garcia-Giralt, Preferences of Spanish-speaking patients for communicating fracture risk in osteoporosis. A substudy of the Risk Communication in Osteoporosis study (RICO Study), Revista de Osteoporosis y Metabolismo Mineral, 10.20960/RevOsteoporosMetabMiner.00048, (2024).
- Kyriakos Souliotis, Christina Golna, Christina Poimenidou, Tatiana Drakopoulou, Memi Tsekoura, Damon Willems, Vasileios Kountouris, Polyzois Makras, Disease Burden and Treatment Preferences Amongst Postmenopausal Women with Severe Osteoporosis in Greece, Patient Preference and Adherence, 10.2147/PPA.S385351, Volume 17, (107-118), (2023).